Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 122
interventional 99
Observational 21
Registry 2

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 63
Drug|placebo 10
Biological 9
Device 3
Other 3
Biological|Drug 2
Biological|placebo 2
Device|Drug 2
Drug|Other 2
Drug|placebo|Procedure 1
Drug|Procedure 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
Brazil 15
India 14
United States 10
Bangladesh 8
Bolivia 7
Colombia 6
NA 4
Peru 4
Sudan 4
Iran, Islamic Republic of 3
Tunisia 3
Afghanistan 2
Ethiopia 2
Ethiopia|Kenya|Sudan|Uganda 2
France 2
Panama 2
United Kingdom 2
Bangladesh|India 1
Cambodia|Congo, The Democratic Republic of the|Nepal|Sudan 1
Colombia|Peru 1
France|Tunisia 1
India|Nepal 1
Israel 1
Kenya|Sudan 1
Kenya|Uganda 1
Pakistan 1

Sites per Study

Site_count Study_Count
1 70
2 17
3 5
4 3
5 1
7 3

Phase

Phase Study_Count
Phase 2 34
Phase 3 21
N/A 13
Phase 1 11
Phase 4 8
Phase 2/Phase 3 7
Phase 1/Phase 2 4
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 17
2 37
3 17
4 8
5 1
NA 19

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 30 12.000 12.00000 25.00 4.00000 72.0 20.0 13.00
1st Qu. 30 95.000 37.50000 62.50 41.25000 75.5 131.0 54.00
Median 30 200.000 45.00000 76.00 60.50000 80.0 399.5 100.50
Mean 30 1914.154 50.18182 64.25 97.35294 103.0 552.3 358.75
3rd Qu. 30 400.000 49.00000 77.75 125.00000 127.0 607.5 280.00
Max. 30 20000.000 140.00000 80.00 414.00000 164.0 3600.0 2000.00

Trial Group Type

group_type Group_Count
Experimental 112
Active Comparator 46
NA 19
Placebo Comparator 13
No Intervention 4
Other 4

Intervention Model

intervention_model Study_Count
Parallel Assignment 70
Single Group Assignment 26
Factorial Assignment 1
Sequential Assignment 1
NA 1

Primary Purpose

primary_purpose Study_Count
Treatment 82
Prevention 10
Other 2
Basic Science 1
Diagnostic 1
Screening 1
Supportive Care 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
Ethiopia 4
Colombia 3
NA 3
United States 3
Belgium 1
Bolivia 1
Brazil 1
India 1
Mali 1
Morocco 1
Peru 1
Tunisia 1

Sites per Study

Site_count Study_Count
1 17
2 3
9 1

Enrollment Metrics

Measure Observational
Min 34.0000
1st Qu 150.0000
Median 228.0000
Mean 655.1905
3rd Qu 438.0000
Max 7000.0000

Observation Model

observational_model Study_Count
Cohort 10
Case-Only 3
Other 3
NA 3
Case-Control 1
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 14
Cross-Sectional 4
NA 3

Registries

Studies by Country

Country Study_Count
United States 2

Sites per Study

Site_count Study_Count
1 2

Enrollment Metrics

Measure Registries
Min 2.00
1st Qu 7.75
Median 13.50
Mean 13.50
3rd Qu 19.25
Max 25.00

Registry Model

observational_model Study_Count
Case-Only 2

Time Perspective

time_perspective Study_Count
Prospective 2

Follow-up

target_duration Study_Count
6 Months 1
9 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03399955 Short Course Regimens for Treatment of PKDL (Sudan) https://ClinicalTrials.gov/show/NCT03399955 Recruiting Drugs for Neglected Diseases 2021-05-09
NCT01484548 Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers https://ClinicalTrials.gov/show/NCT01484548 Completed IDRI 2012-08-31
NCT03311607 Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh https://ClinicalTrials.gov/show/NCT03311607 Completed Medecins Sans Frontieres, Netherlands 2015-10-14
NCT03303898 ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE - https://ClinicalTrials.gov/show/NCT03303898 Recruiting Centre Hospitalier Universitaire de Nice 2017-11-10
NCT03269006 Improved Case Detection and Vector Control for Visceral Leishmaniasis https://ClinicalTrials.gov/show/NCT03269006 Completed International Centre for Diarrhoeal Disease Research, Bangladesh 2016-04-30
NCT03096457 Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia https://ClinicalTrials.gov/show/NCT03096457 Completed Fundacion Nacional de Dermatologia 2018-03-18
NCT03023111 Miltefosine and GM-CSF in Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT03023111 Completed Hospital Universitário Professor Edgard Santos 2019-08-09
NCT02919605 Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis https://ClinicalTrials.gov/show/NCT02919605 Completed Fundação de Medicina Tropical Dr. Heitor Vieira Dourado 2016-01-31
NCT02894008 A Study of a New Leishmania Vaccine Candidate ChAd63-KH https://ClinicalTrials.gov/show/NCT02894008 Completed University of York 2019-09-30
NCT02687971 Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ https://ClinicalTrials.gov/show/NCT02687971 Completed Drugs for Neglected Diseases 2019-08-10
NCT02656797 Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT02656797 Recruiting Soroka University Medical Center 2020-01-31
NCT02431143 Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa https://ClinicalTrials.gov/show/NCT02431143 Completed Drugs for Neglected Diseases 2016-04-30
NCT02193022 Miltefosine for Children With PKDL https://ClinicalTrials.gov/show/NCT02193022 Completed International Centre for Diarrhoeal Disease Research, Bangladesh 2019-06-30
NCT02071758 Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers https://ClinicalTrials.gov/show/NCT02071758 Completed IDRI 2015-12-31
NCT01301937 Low Antimonial Dosage in American Mucosal Leishmaniasis https://ClinicalTrials.gov/show/NCT01301937 Recruiting Oswaldo Cruz Foundation 2020-12-31
NCT01301924 Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT01301924 Completed Oswaldo Cruz Foundation 2016-04-30
NCT01300975 Intralesional Antimony for Bolivian Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT01300975 Completed Fundacion Nacional de Dermatologia 2012-07-31
NCT02011958 Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. https://ClinicalTrials.gov/show/NCT02011958 Completed Drugs for Neglected Diseases 2016-08-31
NCT01988909 WR 279,396 for the Treatment of Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT01988909 Completed Assistance Publique - Hôpitaux de Paris 2015-12-31
NCT01975051 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) https://ClinicalTrials.gov/show/NCT01975051 Completed International Centre for Diarrhoeal Disease Research, Bangladesh 2014-09-30
NCT01845727 Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia https://ClinicalTrials.gov/show/NCT01845727 Completed Drugs for Neglected Diseases 2016-05-31
NCT02025491 Liposomal Amphotericin in Disseminated Leishmaniasis https://ClinicalTrials.gov/show/NCT02025491 Completed Hospital Universitário Professor Edgard Santos 2013-02-28
NCT01790659 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama https://ClinicalTrials.gov/show/NCT01790659 Completed U.S. Army Medical Research and Development Command 2016-01-31
NCT01766830 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) https://ClinicalTrials.gov/show/NCT01766830 Completed University Hospital, Geneva 2014-10-31
NCT01751048 LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine https://ClinicalTrials.gov/show/NCT01751048 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2015-01-31
NCT01661296 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India https://ClinicalTrials.gov/show/NCT01661296 Completed Sarder Patel Medical College 2011-08-31
NCT01644682 Replacement of Insecticides to Control Visceral Leishmaniasis (VL) https://ClinicalTrials.gov/show/NCT01644682 Completed International Centre for Diarrhoeal Disease Research, Bangladesh 2014-12-31
NCT01536795 A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT01536795 Completed U.S. Army Medical Research and Development Command 2007-02-28
NCT01464242 Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT01464242 Completed Centro Internacional de Entrenamiento e Investigaciones Médicas 2015-01-31
NCT01462500 Pharmacokinetics of Miltefosine in Children and Adults https://ClinicalTrials.gov/show/NCT01462500 Completed Centro Internacional de Entrenamiento e Investigaciones Médicas 2014-05-31
NCT01381055 Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT01381055 Completed Hospital Universitário Professor Edgard Santos 2015-01-31
NCT01380314 Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT01380314 Completed Foundation Fader 2010-03-31
NCT01377974 Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis https://ClinicalTrials.gov/show/NCT01377974 Completed Brasilia University Hospital 2013-06-30
NCT01360762 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study https://ClinicalTrials.gov/show/NCT01360762 Completed Institute of Tropical Medicine, Belgium 2015-11-30
NCT01328457 An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh https://ClinicalTrials.gov/show/NCT01328457 Completed PATH 2011-05-31
NCT04340128 Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL) https://ClinicalTrials.gov/show/NCT04340128 Completed Tehran University of Medical Sciences 2007-10-31
NCT03999970 A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol https://ClinicalTrials.gov/show/NCT03999970 Completed University of York 2019-12-23
NCT03969134 A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL https://ClinicalTrials.gov/show/NCT03969134 Recruiting University of York 2021-10-31
NCT03929016 Single Oral Dose Escalation Study of DNDI-0690 in Healthy Male Subjects https://ClinicalTrials.gov/show/NCT03929016 Recruiting Drugs for Neglected Diseases 2019-09-30
NCT03829917 Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT03829917 Recruiting Fundacion Nacional de Dermatologia 2020-02-01
NCT03641339 Defining Skin Immunity of a Bite of Key Insect Vectors in Humans https://ClinicalTrials.gov/show/NCT03641339 Completed National Institutes of Health Clinical Center (CC) 2019-08-13
NCT03636659 Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition https://ClinicalTrials.gov/show/NCT03636659 Completed Aurobindo Pharma Ltd 2019-04-05
NCT03445897 Miltefosine Plus IL Pentamidine for Bolivian CL https://ClinicalTrials.gov/show/NCT03445897 Completed AB Foundation 2018-01-31
NCT01240473 A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh https://ClinicalTrials.gov/show/NCT01240473 Completed International Centre for Diarrhoeal Disease Research, Bangladesh 2008-03-31
NCT01122771 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh https://ClinicalTrials.gov/show/NCT01122771 Completed Drugs for Neglected Diseases 2014-03-31
NCT01083576 Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama https://ClinicalTrials.gov/show/NCT01083576 Completed U.S. Army Medical Research and Development Command 2011-06-30
NCT01069198 A Community Trial for Visceral Leishmaniasis (VL) https://ClinicalTrials.gov/show/NCT01069198 Completed International Centre for Diarrhoeal Disease Research, Bangladesh 2010-10-31
NCT01067443 Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa https://ClinicalTrials.gov/show/NCT01067443 Completed Drugs for Neglected Diseases 2011-06-30
NCT01050907 Miltefosine to Treat Mucocutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT01050907 Completed Knight Therapeutics (USA) Inc 2015-02-28
NCT01050777 Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT01050777 Completed Tehran University of Medical Sciences 2012-01-31
NCT01032382 Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK) https://ClinicalTrials.gov/show/NCT01032382 Completed U.S. Army Medical Research and Development Command 2011-03-31
NCT01032187 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children https://ClinicalTrials.gov/show/NCT01032187 Completed University of Brasilia 2010-01-31
NCT01011309 A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT01011309 Completed IDRI 2011-05-31
NCT00996463 Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients https://ClinicalTrials.gov/show/NCT00996463 Completed Waisenmedizin e. V. Promoting Access to Essential Medicine 2010-09-30
NCT00982774 Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL https://ClinicalTrials.gov/show/NCT00982774 Completed IDRI 2011-04-30
NCT00973128 Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT00973128 Completed Hospital Universitário Professor Edgard Santos 2006-10-31
NCT00947362 Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul https://ClinicalTrials.gov/show/NCT00947362 Completed Waisenmedizin e. V. Promoting Access to Essential Medicine NA
NCT00884377 Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT00884377 Completed U.S. Army Medical Research and Development Command 2009-01-31
NCT00876824 To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar https://ClinicalTrials.gov/show/NCT00876824 Completed Bharat Serums and Vaccines Limited 2011-01-31
NCT02530697 The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: A Clinical Trial in Brazil https://ClinicalTrials.gov/show/NCT02530697 Recruiting University of Brasilia 2020-07-31
NCT03294161 Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT03294161 Completed Hospital Universitário Professor Edgard Santos 2017-04-30
NCT03129646 Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa https://ClinicalTrials.gov/show/NCT03129646 Recruiting Drugs for Neglected Diseases 2019-11-30
NCT00703924 Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World https://ClinicalTrials.gov/show/NCT00703924 Completed U.S. Army Medical Research and Development Command 2004-11-30
NCT00696969 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis https://ClinicalTrials.gov/show/NCT00696969 Completed Drugs for Neglected Diseases 2010-01-31
NCT00662012 Sodium Stibogluconate Treatment of Leishmaniasis https://ClinicalTrials.gov/show/NCT00662012 Completed U.S. Army Medical Research and Development Command 2007-10-31
NCT00657618 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis https://ClinicalTrials.gov/show/NCT00657618 Completed U.S. Army Medical Research and Development Command 2010-04-30
NCT00633009 Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen https://ClinicalTrials.gov/show/NCT00633009 Completed Nielsen BioSciences, Inc. 2009-09-30
NCT00629031 An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis https://ClinicalTrials.gov/show/NCT00629031 Completed Banaras Hindu University 2008-02-29
NCT00628719 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis https://ClinicalTrials.gov/show/NCT00628719 Completed Banaras Hindu University 2008-08-31
NCT00606580 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) https://ClinicalTrials.gov/show/NCT00606580 Completed U.S. Army Medical Research and Development Command 2011-07-31
NCT00604955 Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis https://ClinicalTrials.gov/show/NCT00604955 Completed PATH 2008-12-31
NCT00600548 Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil) https://ClinicalTrials.gov/show/NCT00600548 Completed Hospital Universitário Professor Edgard Santos 2009-03-31
NCT00523965 Combination Therapy in Indian Visceral Leishmaniasis https://ClinicalTrials.gov/show/NCT00523965 Completed Banaras Hindu University 2009-08-31
NCT00497601 A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar https://ClinicalTrials.gov/show/NCT00497601 Completed Banaras Hindu University 2008-07-31
NCT00490230 Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application https://ClinicalTrials.gov/show/NCT00490230 Completed U.S. Army Medical Research and Development Command 2007-06-30
NCT00486382 Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India https://ClinicalTrials.gov/show/NCT00486382 Completed IDRI 2008-11-30
NCT00480883 Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol https://ClinicalTrials.gov/show/NCT00480883 Completed Combined Military Hospital, Pakistan 2008-06-30
NCT00471705 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. https://ClinicalTrials.gov/show/NCT00471705 Completed Universidad de Antioquia 2008-08-31
NCT00469495 Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT00469495 Completed Hospital Universitário Professor Edgard Santos 2008-09-30
NCT00381394 A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis. https://ClinicalTrials.gov/show/NCT00381394 Completed GlaxoSmithKline 2007-09-14
NCT00373776 Miltefosine for Mucosal Leishmaniasis https://ClinicalTrials.gov/show/NCT00373776 Completed AB Foundation NA
NCT00373568 Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis https://ClinicalTrials.gov/show/NCT00373568 Completed AB Foundation NA
NCT00371995 Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar https://ClinicalTrials.gov/show/NCT00371995 Completed Banaras Hindu University 2009-08-31
NCT00370825 Combination Chemotherapy for the Treatment of Indian Kala-Azar https://ClinicalTrials.gov/show/NCT00370825 Completed Banaras Hindu University NA
NCT00351520 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica https://ClinicalTrials.gov/show/NCT00351520 Completed Tehran University of Medical Sciences NA
NCT00318721 Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar https://ClinicalTrials.gov/show/NCT00318721 Completed London School of Hygiene and Tropical Medicine 2008-12-31
NCT00317980 Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT00317980 Completed University of Brasilia 2008-03-31
NCT00310505 Amphotericin B Treatment in Visceral Leishmaniasis https://ClinicalTrials.gov/show/NCT00310505 Completed Banaras Hindu University NA
NCT00257530 Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT00257530 Completed Drugs for Neglected Diseases 2006-06-30
NCT00255567 Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis https://ClinicalTrials.gov/show/NCT00255567 Completed Drugs for Neglected Diseases 2010-01-31
NCT00233545 Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia https://ClinicalTrials.gov/show/NCT00233545 Completed AB Foundation NA
NCT00216346 Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis https://ClinicalTrials.gov/show/NCT00216346 Completed PATH NA
NCT00121862 Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite https://ClinicalTrials.gov/show/NCT00121862 Completed IDRI NA
NCT00121849 Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite https://ClinicalTrials.gov/show/NCT00121849 Completed IDRI NA
NCT00111553 Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT00111553 Completed IDRI NA
NCT00111514 Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis https://ClinicalTrials.gov/show/NCT00111514 Completed IDRI NA
NCT00818818 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients https://ClinicalTrials.gov/show/NCT00818818 Completed University of Brasilia 2010-01-31
NCT00001906 Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants https://ClinicalTrials.gov/show/NCT00001906 Completed National Institutes of Health Clinical Center (CC) NA
NCT00004755 Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil https://ClinicalTrials.gov/show/NCT00004755 Completed Office of Rare Diseases (ORD) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03013673 Predicting Visceral Leishmaniasis in HIV Infected Patients https://ClinicalTrials.gov/show/NCT03013673 Recruiting Institute of Tropical Medicine, Belgium 2021-10-31
NCT02979002 Accuracy of a Rapid Diagnostic Test for Cutaneous Leishmaniasis in Morocco https://ClinicalTrials.gov/show/NCT02979002 Completed National School of Public Health, Morocco 2017-08-31
NCT00344188 Diagnosis and Treatment of Leishmanial Infections https://ClinicalTrials.gov/show/NCT00344188 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02431429 Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT02431429 Completed Knight Therapeutics (USA) Inc 2018-02-23
NCT01896362 The Healthcare Professionals and the Leishmaniasis https://ClinicalTrials.gov/show/NCT01896362 Completed Centro de Pesquisas René Rachou 2010-10-31
NCT01865032 Evaluation of CL Detectâ„¢ Rapid Test to Detect Cutaneous Leishmaniasis https://ClinicalTrials.gov/show/NCT01865032 Completed U.S. Army Medical Research and Development Command 2013-08-31
NCT01769612 Evaluation of a Rapid Diagnostic Device, CL Detect, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia https://ClinicalTrials.gov/show/NCT01769612 Completed U.S. Army Medical Research and Development Command 2013-08-31
NCT04004754 Outcomes of Complicated CL in Ethiopia Treated With Miltefosine https://ClinicalTrials.gov/show/NCT04004754 Completed Institute of Tropical Medicine, Belgium 2020-04-01
NCT04001335 Diagnosis of Cutaneous Leishmaniasis Using the CL-detect Rapid Test in Travelers and Migrants in Belgium https://ClinicalTrials.gov/show/NCT04001335 Recruiting Institute of Tropical Medicine, Belgium 2020-09-01
NCT03993093 Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre https://ClinicalTrials.gov/show/NCT03993093 Completed Singh, Ranjan Kumar, M.D. 2020-02-28
NCT03837431 Cutaneous Leishmaniasis Diagnostic Study https://ClinicalTrials.gov/show/NCT03837431 Recruiting Institute of Tropical Medicine, Belgium 2021-12-01
NCT03435419 Evaluation of Point-of-care Tests for the Diagnosis of Cutaneous Leishmaniasis in Afghanistan https://ClinicalTrials.gov/show/NCT03435419 Completed Foundation for Innovative New Diagnostics, Switzerland 2016-06-22
NCT03762070 Evaluation of a Diagnostic Device, CL Detectâ„¢ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru https://ClinicalTrials.gov/show/NCT03762070 Recruiting Naval Medical Research Center 2019-03-31
NCT02148822 Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia https://ClinicalTrials.gov/show/NCT02148822 Completed Instituto de Salud Carlos III 2009-12-31
NCT04003532 LAMP Assay for the Diagnosis of Visceral Leishmaniasis https://ClinicalTrials.gov/show/NCT04003532 Recruiting Mekelle University 2022-06-30
NCT00401557 Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection https://ClinicalTrials.gov/show/NCT00401557 Completed Yale University NA
NCT00401349 Expression of Mif Alleles in Individuals With Leishmaniasis https://ClinicalTrials.gov/show/NCT00401349 Completed Yale University NA
NCT00401297 Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes https://ClinicalTrials.gov/show/NCT00401297 Completed Yale University NA
NCT00344084 Surveillance for Leishmaniasis Skin Lesions in Mali https://ClinicalTrials.gov/show/NCT00344084 Completed National Institutes of Health Clinical Center (CC) NA
NCT00342823 Immunogenetics of Visceral Leishmaniasis https://ClinicalTrials.gov/show/NCT00342823 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001169 Clinical Investigation of Infections Due to Leishmanial Parasites https://ClinicalTrials.gov/show/NCT00001169 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02429505 Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry https://ClinicalTrials.gov/show/NCT02429505 Recruiting Knight Therapeutics (USA) Inc 2020-03-31
NCT02427308 Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry https://ClinicalTrials.gov/show/NCT02427308 Recruiting Knight Therapeutics (USA) Inc 2025-03-31